@elizajane1983's 10-month Zepbound journey, fact-checked
Quick answer
This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health. No specific medical claims are made verbally. The clinical relevance centers on the potential interaction between GLP-1-induced delayed gastric emptying and levothyroxine absorption, a consideration that endocrinologists have flagged but that rarely appears in patient-facing GLP-1 content.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @elizajane1983 actually say?
Honestly? Almost nothing factual. The transcript from this 28K-view TikTok is song lyrics, not health commentary. The words captured are something like "I grew good enough" and "damn all of the night" repeated over a beat. This is a transformation video set to music, not a verbal claims video.
The actual information here comes from the caption, not the spoken content. The caption tells us the creator has been on Zepbound for 10 months, identifies as someone with hypothyroidism, and tags the IVIM Health affiliate program. That context matters more than anything said aloud in the clip.
So let's be clear about scope: we're fact-checking what a 10-month Zepbound journey video implies and what the caption signals, because the transcript itself gives us nothing to work with medically.
Does the science back this up?
The implied premise, that tirzepatide (Zepbound) produces meaningful weight loss over 10 months, is well-supported by evidence. But the hypothyroidism angle in the hashtags deserves scrutiny, because it's more complicated than most GLP-1 content acknowledges.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide at the highest dose produced an average 22.5% body weight reduction over 72 weeks in adults with obesity. Ten months sits inside that window. Those are real, significant numbers.
The hypothyroidism piece is trickier. Levothyroxine absorption can be affected by changes in gut motility, which GLP-1 receptor agonists slow significantly. A 2023 case series in Thyroid journal flagged that some patients on GLP-1 agonists required levothyroxine dose adjustments. Whether the creator experienced this isn't clear, but it's clinically relevant context that most TikTok transformation videos completely skip.
What did they get wrong (or right)?
There's nothing medically wrong said out loud here, because nothing medically specific was said. That's actually a point in this video's favor compared to many GLP-1 creator posts that make explicit dosing claims or promise specific outcomes.
What the video does implicitly suggest, through hashtags and before-and-after framing, is that a 10-month Zepbound run produces dramatic visible results. That implication is broadly consistent with clinical data, though individual results vary significantly. SURMOUNT-1 showed a wide distribution of outcomes, not a uniform 22% loss for every participant.
The IVIM Health affiliate tag is worth flagging. This is a commercial relationship, and viewers deserve to know that. The FTC requires disclosure of material connections in sponsored content. Hashtag disclosure like "#ivimaffiliate" is technically present but easy to miss in a list of 11 other hashtags. That's a gray area that the FTC has pushed back on in enforcement letters.
- No false medical claims made verbally: accurate
- Hypothyroidism complexity not addressed: a gap, not a lie
- Affiliate disclosure present but minimized: borderline compliant
What should you actually know?
If you have hypothyroidism and you're considering a GLP-1 medication like tirzepatide, talk to the clinician managing your thyroid before you start. This is not a scare tactic. Slowed gastric emptying from GLP-1 agonists can change how consistently your levothyroxine absorbs, and an undertreated thyroid can actually make weight loss harder. Your thyroid panel may need monitoring after you start.
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is not a lifestyle supplement. It works through dual GIP and GLP-1 receptor agonism, which is a different mechanism than semaglutide-only drugs like Wegovy.
Transformation videos are not clinical data. A single person's 10-month result, however dramatic, tells you nothing reliable about what your body will do. The variance in GLP-1 outcomes is significant, and factors like baseline weight, diet, activity, other medications, and genetics all play a role that no before-and-after photo can capture.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @elizajane1983's 10-month Zepbound journey, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health.
FormBlends verdict
This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health. No specific medical claims are made verbally. The clinical relevance centers on the potential interaction between GLP-1-induced delayed gastric emptying and levothyroxine absorption, a consideration that endocrinologists have flagged but that rarely appears in patient-facing GLP-1 content.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health. No specific medical claims are made verbally. The clinical relevance centers on the potential interaction between GLP-1-induced delayed gastric emptying and levothyroxine absorption, a consideration that endocrinologists have flagged but that rarely appears in patient-facing GLP-1 content.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found average 22.5% body weight reduction with tirzepatide 15mg over 72 weeks, but individual results ranged widely.
- Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found average 22.5% body weight reduction with tirzepatide 15mg over 72 weeks, but individual results ranged widely.
- Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.
- A 2023 case series in Thyroid journal identified that GLP-1-induced delayed gastric emptying can reduce levothyroxine absorption reliability in some patients.
- FDA approval for Zepbound requires a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. It is not approved for general weight management in otherwise healthy adults.
- FTC 2023 endorsement guidance states that affiliate disclosures must be clear and conspicuous, not buried in hashtag lists, a standard many GLP-1 creator posts technically fail.
- This video contained no verbal medical claims. The transcript is song lyrics. Any implied health messaging comes from caption framing and hashtag context, not spoken content.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Elizabeth · TikTok creator
28.3K views on this video
10 months on Zepbound! GLP1 journey Zepbound journey. #glp1 #weightloss #glp1community #glp1journey#healthjourney #zepboundjourney #hypothyroidism #weightlosstransformation #fitnessmotivation #zepbou
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Elizabeth, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.